COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy
Biomolecules · 2024
DOI: 10.3390/biom14070777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Mariana Bondrescu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: Neuregulin-1, Catechol O-Methyltransferase, Risperidone, Schizophrenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babes” University of Medicine and Pharmacy Timisoara.
Abstract (Originalsprache)
Pharmacogenetic markers are current targets for the personalized treatment of psychosis. Limited data exist on COMT and NRG1 polymorphisms in relation to risperidone treatment. This study focuses on the impact of COMT rs4680 and NRG1 (rs35753505, rs3924999) polymorphisms on risperidone treatment in schizophrenia spectrum disorders (SSDs). This study included 103 subjects with SSD treated with risperidone monotherapy. COMT rs4680, NRG1 rs35753505, and rs3924999 were analyzed by RT-PCR. Participants were evaluated via the Positive and Negative Syndrome Scale (PANSS) after six weeks. Socio-demographic and clinical characteristics were collected. COMT rs4680 genotypes significantly differed in PANSS N scores at admission: AG>AA genotypes (p = 0.03). After six weeks of risperidone, PANSS G improvement was AA>GG (p = 0.05). The PANSS total score was as follows: AA>AG (p = 0.04), AA>GG (p = 0.02). NRG1 rs35753504 genotypes significantly differed across educational levels, with CC>CT (p = 0.02), and regarding the number of episodes, TT>CC, CT>CC (p = 0.01). The PANSS total score after six weeks of treatment showed a better improvement for TT
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
- Timis County Emergency Clinical Hospital "Pius Brinzeu", Liviu Rebreanu 156, 300723 Timisoara, Romania.
- Doctoral School, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
- Discipline of Medical Genetics, Department of Microscopic Morphology, Center of Genomic Medicine "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
- Faculty of Mathematics and Informatics, West University of Timisoara, Vasile Parvan 4, 300223 Timisoara, Romania.
ORCID-Profile: Mariana Bondrescu, Ion Papava, Nicoleta Ioana Andreescu
Förderung
- “Victor Babes” University of Medicine and Pharmacy Timisoara
Zitieren
APA
Bondrescu, M., Dehelean, L., Farcas, S. S., Papava, I., Nicoras, V., Mager, D. V., Grecescu, A. E., Podaru, P. A., & Andreescu, N. I. (2024). COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy. Biomolecules. https://doi.org/10.3390/biom14070777
Vancouver
Bondrescu M, Dehelean L, Farcas SS, Papava I, Nicoras V, Mager DV, et al. COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy. Biomolecules. 2024. doi:10.3390/biom14070777
BibTeX
@article{Bondrescu2024,
author = {Bondrescu, Mariana and Dehelean, Liana and Farcas, Simona Sorina and Papava, Ion and Nicoras, Vlad and Mager, Dana Violeta and Grecescu, Anca Eliza and Podaru, Petre Adrian and Andreescu, Nicoleta Ioana},
title = {COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14070777}
}
EUVIMED